Steve Scala, an analyst from TD Cowen, reiterated the Buy rating on Eli Lilly & Co. The associated price target remains the same with $960.00.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Steve Scala has given his Buy rating due to a combination of factors including Eli Lilly & Co’s strong growth prospects and consistent innovation. The company’s participation in several key panels at the TD Cowen Therapeutics Conference highlights its leadership in areas such as diabetes, obesity, breast cancer, cardiology, and pain management.
Furthermore, Eli Lilly’s compelling valuation metrics make it an attractive investment. The company’s pipeline, featuring promising products like orforglipron and Mounjaro/Zepbound, as well as recent approvals like Inluriyo, underscore its potential for continued success. These elements collectively contribute to the positive outlook for Eli Lilly’s stock.
In another report released on October 3, Morgan Stanley also maintained a Buy rating on the stock with a $1,023.00 price target.